Staley Capital Advisers Inc. Purchases 447,050 Shares of Henry Schein, Inc. $HSIC

Staley Capital Advisers Inc. lifted its position in Henry Schein, Inc. (NASDAQ:HSIC) by 12,115.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 450,740 shares of the company’s stock after buying an additional 447,050 shares during the quarter. Henry Schein comprises approximately 1.4% of Staley Capital Advisers Inc.’s holdings, making the stock its 24th largest position. Staley Capital Advisers Inc.’s holdings in Henry Schein were worth $33,220,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. CYBER HORNET ETFs LLC acquired a new position in Henry Schein during the 2nd quarter worth $25,000. MUFG Securities EMEA plc acquired a new stake in shares of Henry Schein in the second quarter valued at about $27,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Henry Schein in the fourth quarter valued at about $30,000. Federated Hermes Inc. bought a new position in shares of Henry Schein in the fourth quarter worth about $32,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Henry Schein in the fourth quarter worth about $37,000. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HSIC has been the subject of several recent analyst reports. BTIG Research upgraded Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a research note on Thursday, June 11th. UBS Group reaffirmed a “neutral” rating and issued a $85.00 price target (down from $87.00) on shares of Henry Schein in a research report on Wednesday, May 6th. Morgan Stanley reissued an “underweight” rating and issued a $64.00 price objective (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Robert W. Baird set a $97.00 price objective on shares of Henry Schein in a research note on Wednesday, May 6th. Finally, BMO Capital Markets started coverage on shares of Henry Schein in a research report on Wednesday. They set a “market perform” rating and a $85.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $87.64.

Henry Schein Stock Down 4.2%

NASDAQ HSIC opened at $83.22 on Thursday. Henry Schein, Inc. has a twelve month low of $61.94 and a twelve month high of $89.29. The stock has a market cap of $9.48 billion, a PE ratio of 25.14, a PEG ratio of 1.67 and a beta of 0.81. The firm has a 50-day simple moving average of $77.67 and a 200 day simple moving average of $77.25. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.12. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The firm had revenue of $3.37 billion for the quarter, compared to analyst estimates of $3.34 billion. During the same period in the previous year, the company posted $1.15 earnings per share. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, research analysts forecast that Henry Schein, Inc. will post 5.32 EPS for the current year.

Insider Activity

In other news, Director William K. Daniel acquired 10,000 shares of the stock in a transaction dated Monday, May 11th. The shares were acquired at an average cost of $69.19 per share, for a total transaction of $691,900.00. Following the completion of the transaction, the director owned 20,000 shares in the company, valued at approximately $1,383,800. This trade represents a 100.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.89% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.